Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
enGene Holdings ( (ENGN) ) just unveiled an update.
On May 5, 2026, enGene USA amended and restated the employment agreement with Dr. Hussein Sweiti, effective May 6, 2026, updating his compensation to a $561,750 base salary, a 40% annual bonus opportunity, and continued benefit eligibility. The new terms also waive any repayment of his prior sign-on bonus and, importantly, allow him, from June 1, 2026, to resign with five business days’ notice while retaining post-termination severance, tightening alignment between executive incentives and the company’s evolving needs.
On May 7, 2026, enGene reported updated interim data from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk BCG-unresponsive non-muscle invasive bladder cancer, showing a 54% complete response rate at any time, a 43% six-month complete response rate, and a low 3.2% progression rate to muscle-invasive or more advanced disease. While durability metrics, including a Kaplan-Meier estimated 12-month complete response rate of 25% and median duration of response of 37.3 weeks, fell short of internal expectations and recent enrollees showed lower response rates, the therapy’s largely mild safety profile and regulatory designations position enGene to continue FDA engagement and maintain a potential path toward a future biologics license filing, with further data to be shared at a major urology meeting in May 2026.
The most recent analyst rating on (ENGN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
The score is held down primarily by weak financial performance (no revenue and heavy cash burn) and a technically weak price trend below key moving averages. Positive corporate/regulatory milestones provide some offset, while valuation signals are limited due to a negative P/E and no indicated dividend yield.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Therapeutics Inc., listed on Nasdaq as ENGN, is a clinical-stage, non-viral genetic medicines company developing novel gene therapies for high-risk, non-muscle invasive bladder cancer. Its lead investigational therapy, detalimogene voraplasmid, is designed for intravesical administration to elicit a localized anti-tumor immune response in Bacillus Calmette-Guérin-unresponsive patients. Detalimogene is built on enGene’s proprietary Dually Derivatized Oligochitosan platform, which aims to overcome limitations of viral-based gene therapies and simplify manufacturing, handling, and administration. The therapy has received RMAT and Fast Track designations and is included in the FDA’s CMC Development and Readiness Pilot program, underscoring its potential to address a significant unmet medical need in bladder cancer.
Average Trading Volume: 392,213
Technical Sentiment Signal: Hold
Current Market Cap: $592.9M
Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.